ArticleBMC nephrology2026
Survival after kidney retransplantation in Türkiye: a developing country perspective.
Article in BMC nephrology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundKidney retransplantation has emerged as a crucial treatment approach as the number of patients experiencing graft failure increases. However, evidence regarding long-term outcomes remains scarce in developing countries due to multiple barriers.
methodsThis single-center retrospective study included 43 second kidney transplant recipients who were transplanted between January 1993 and April 2023 and 120 matched first transplant recipients based on recipient age and sex, donor age and sex, donor type, HLA-A, HLA-B, and HLA-DR mismatch number, and transplantation year. Recipient-donor characteristics, post-transplant outcomes, death-censored graft and patient survival were evaluated.
resultsThe mean age of the study population (n = 163) was 40.75 ± 10.96 years, with male predominance (57.6%). 24% of grafts were received from deceased donors. The retransplantation group demonstrated higher rates of flow cytometry cross-match B lymphocyte positivity, desensitization, and induction therapy, despite similar numbers of HLA mismatches and donor-specific antibody positivity when compared to first-time transplant recipients. No differences were observed between the groups regarding kidney function or acute rejection rates during the follow-up period. Death-censored graft survival and patient survival rates at 3, 5, and 10-years were 94.3%, 88.0%, 66.7% and 100.0%, 100.0%, 66.7% for the retransplantation group, compared to 98.1%, 87.9%, 57.6% and 100.0%, 93.5%, and 82.4% for the first transplantation group, respectively. Previous transplantation was not a risk factor for graft or patient loss (p = 0.554 and p = 0.588, respectively). Increased recipient age (HR = 0.984, 95%CI = 0.969-1.000, p = 0.049) and elevated donor eGFR (HR = 0.902, 95%CI = 0.840–0.968, p = 0.004) were associated with better death-censored graft survival, while increased recipient age (HR = 1.055, 95% CI = 1.035–1.076, p < 0.001) and deceased donor (HR = 2.176, 95% CI = 1.286–3.682, p = 0.004) were independent risk factors for patient loss.
conclusionKidney transplantation after graft loss demonstrated comparable short and long-term graft and patient survival outcomes to the first transplants in Türkiye. Kidney retransplantation has the potential to improve long-term patient outcomes in developing countries, after addressing economic and medical barriers, and regional disparities in healthcare access.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.